A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Evan Hersh, MD
AmpliMed Corporation
Study Director - Steven Cohen, MD
Fox Chase Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
48 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Birmingham Hematology and Oncology- Us Oncology
Birmingham, Alabama, United States
- Az Onc Associates D.B.A. Hematology Oncology- Us Oncology
Tucson, Arizona, United States
- Arizona Clinical Research Center
Tucson, Arizona, United States
- Rocky Mountain Cancer Center- Us Oncology
Denver, Colorado, United States
- Ocala Oncology Center- Us Oncology
Ocala, Florida, United States
- Cancer Centers of Florida- Us Oncology
Orlando, Florida, United States
- Peachtree Hematology and Oncology Consultants
Atlanta, Georgia, United States
- Hematology Oncology Associates of Illinois- Us Oncology
Chicago, Illinois, United States
- Cancer Care & Hematolog Specialists of Chicagoland- Us Oncology
Niles, Illinois, United States
- Central Indiana Cancer Centers- Us Oncology
Indianapolis, Indiana, United States
- Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
- Hope Center- Us Oncology
Terre Haute, Indiana, United States
- University of Kentucky, Hematology/oncology/bmt Clinical Research
Lexington, Kentucky, United States
- Lahey Clinic
Burlington, Massachusetts, United States
- University of Michigan
Ann Arbor, Michigan, United States
- University of Minnesota
Minneapolis, Minnesota, United States
- Kansas City Cancer Center, Llc- Us Oncology
Kansas City, Missouri, United States
- Comprehensive Cancer Centers of Nevada- Us Oncology
Las Vegas, Nevada, United States
- Hunterdon Regional Cancer Center
Flemington, New Jersey, United States
- Hematology Oncology Associates
Mount Holly, New Jersey, United States
- Hematology Oncology Associates
Albuquerque, New Mexico, United States
- University of New Mexico
Albuquerque, New Mexico, United States
- University of New Mexico Cancer Center South
Las Cruces, New Mexico, United States
- New Mexico Cancer Care Associates- Us Oncology
Santa Fe, New Mexico, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Cancer Center of North Carolina- Us Oncology
Raleigh, North Carolina, United States
- Medical Onc Assoc of Wyoming Valley, Pc- Us Oncology
Kingston, Pennsylvania, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
- Pottstown Memorial Medical Center
Pottstown, Pennsylvania, United States
- Associates in Hematology-Oncology P.C. Us Oncology
Upland, Pennsylvania, United States
- Reading Hospital Regional Medical Center
West Reading, Pennsylvania, United States
- Sanford Clinic
Sioux Falls, South Dakota, United States
- Texas Oncology - Amarillo- Us Oncology
Amarillo, Texas, United States
- Mamie Mcfaddin Ward Cancer Center, Texas Oncology- Us Oncology
Beaumont, Texas, United States
- Texas Oncology P.A.- Bedford- Us Oncology
Bedford, Texas, United States
- Methodist Charlton Cancer Center - Texas Oncology- Us Oncology
Dallas, Texas, United States
- Texas Cancer Center at Medical City- Us Oncology
Dallas, Texas, United States
- Texas Oncology P.A. - Dallas- Us Oncology
Dallas, Texas, United States
- Texas Oncology - Odessa- Us Oncology
Odessa, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2008
- Primary completion
- 31 May 2010
- Completion
- 30 Jun 2010
- Last update posted
- 20 Mar 2019
- Registered enrollment
- 142
- Registry id
- NCT00637247
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.